https://www.selleckchem.com/pr....oducts/mcc950-sodium
Objective This study aimed to determine whether infants who were treated with intravitreal bevacizumab (IV for retinopathy of prematurity (ROP) were at higher risk of death or neurodevelopmental impairment (NDI) when compared with infants who were not treated with IVB (Laser only). Study design This retrospective study included 146 infants born from 2009 through 2016 with a birth weight (BW) less then 1,000 g, gestational age less then 27 weeks, and required ROP therapy. Death and NDI rates were assessed at 18 to 24 months'
Like
Comment
Share
